R1 RCM Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM or view top-rated stocks.

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

R1 RCM saw a increase in short interest in May. As of May 28th, there was short interest totaling 5,100,000 shares, an increase of 43.3% from the May 13th total of 3,560,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 4.3% of the company's shares are short sold.
View R1 RCM's Short Interest.

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for R1 RCM.

R1 RCM Inc. (NASDAQ:RCM) released its quarterly earnings data on Tuesday, May, 4th. The healthcare provider reported ($2.37) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.08 by $2.45. The healthcare provider had revenue of $342.60 million for the quarter, compared to analysts' expectations of $338.74 million. R1 RCM had a trailing twelve-month return on equity of 74.82% and a net margin of 9.65%. The business's quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.05 EPS.
View R1 RCM's earnings history.

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RCM stock has increased by 120.3% and is now trading at $22.38.
View which stocks have been most impacted by COVID-19.

R1 RCM updated its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.41 billion-$1.46 billion, compared to the consensus revenue estimate of $1.45 billion.

6 brokerages have issued twelve-month target prices for R1 RCM's shares. Their forecasts range from $22.00 to $35.00. On average, they expect R1 RCM's stock price to reach $28.83 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for R1 RCM or view top-rated stocks among Wall Street analysts.

253 employees have rated R1 RCM CEO Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

Some companies that are related to R1 RCM include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of RCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.52%), Paradigm Capital Management Inc. NY (1.47%), Bank of New York Mellon Corp (1.04%), Geode Capital Management LLC (0.77%), Nuveen Asset Management LLC (0.74%) and Praesidium Investment Management Company LLC (0.64%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan and Michael C Feiner.
View institutional ownership trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, SCW Capital Management LP, Bank of New York Mellon Corp, Clearbridge Investments LLC, Panagora Asset Management Inc., Boston Partners, Glenmede Trust Co. NA, and Royce & Associates LP. Company insiders that have sold R1 RCM company stock in the last year include Achi Series Lllp Tcp-Asc, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, and Michael C Feiner.
View insider buying and selling activity for R1 RCM or view top insider-selling stocks.

RCM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Allianz Asset Management GmbH, Millennium Management LLC, Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Geode Capital Management LLC, Compagnie Lombard Odier SCmA, and Mirae Asset Global Investments Co. Ltd.. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM or or view top insider-buying stocks.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCM stock can currently be purchased for approximately $22.38.

R1 RCM has a market capitalization of $5.86 billion and generates $1.27 billion in revenue each year. The healthcare provider earns $117.10 million in net income (profit) each year or $0.28 on an earnings per share basis.

R1 RCM employs 20,200 workers across the globe.

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

R1 RCM was founded in 2003.

The official website for R1 RCM is www.r1rcm.com.

R1 RCM is headquartered at 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected]